Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LONDON, July 09, 2018 (GLOBE NEWSWIRE) -- ASLAN announced in July 2018 that it has received clinical trial authorisation in Singapore to conduct a Phase I study of ASLAN004 for the treatment of...
-
LONDON, July 03, 2018 (GLOBE NEWSWIRE) -- In this note, we revisit SDX’s 2017/2018 gas discoveries in Morocco and Egypt and look ahead at the company’s plans to leverage this success to deepen its...
-
LONDON, June 28, 2018 (GLOBE NEWSWIRE) -- In April, Quantum Genomics announced it would be moving forward with the Phase IIb trial in heart failure and has recently announced the design of this...
-
LONDON, U.K., June 21, 2018 (GLOBE NEWSWIRE) -- BONESUPPORT is commercialising synthetic bone graft substitutes. The company invests in R&D to support continued development of innovative...
-
LONDON, June 12, 2018 (GLOBE NEWSWIRE) -- Over the past year, DeA Capital (DeA) has continued to make good progress in implementing the growth strategy for its alternative asset management (AAM)...
-
LONDON, June 11, 2018 (GLOBE NEWSWIRE) -- The development of Hurricane’s Lancaster early production system (EPS) remains on track for H119 first oil. We estimate a 1 January 2018 point-forward IRR...
-
LONDON, June 08, 2018 (GLOBE NEWSWIRE) -- Findel (FDL) is seeing outstanding success with its online-led value retail strategy. FY18’s 21% PBT growth includes a strong Black Friday and Christmas...
-
LONDON, June 08, 2018 (GLOBE NEWSWIRE) -- ASLAN presented data at ASCO from a Phase Ib dosing study examining varlitinib in combination with carboplatin, paclitaxel and Herceptin. Patients were...
-
LONDON, June 07, 2018 (GLOBE NEWSWIRE) -- InMed is a Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Through its biosynthesis platform, the...
-
NEW YORK, May 12, 2017 (GLOBE NEWSWIRE) -- Edison Investment Research Inc. (“Edison”), an investment research and advisory company, wishes to comment on statements made by Akari Therapeutics...